Scarica l'app Stockscreener
11.30
0.36%
0.045
Dopo l'orario di chiusura:
11.30
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VERV Giù?
Forum
Previsione
Verve Therapeutics Inc Borsa (VERV) Ultime notizie
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc.VERV - Business Wire
Verve Therapeutics Stock Price, Quotes and Forecasts - Benzinga
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - MSN
Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus
Lilly to acquire Verve Therapeutics for $1.3 billion - C&EN
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges - Investing.com
Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition - TipRanks
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - MSN
Verve Therapeutics downgraded to Hold from Buy at Canaccord - Yahoo Finance
Eli Lilly nears $1.3B deal for Verve Therapeuticsreport - MSN
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
Beyond Obesity: Eli Lilly’s Genetic Medicine Bet On Verve Therapeutics - Forbes
This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Verve Therapeutics (VERV) Rating to Neutral | VERV Stock News - GuruFocus
Jefferies Downgrades Verve Therapeutics (VERV), Lowers Price Tar - GuruFocus
Verve Therapeutics (VERV): Downgrade and Updated Price Target | - GuruFocus
Lilly to acquire Verve Therapeutics to advance gene editing treatments - World Pharmaceutical Frontiers
Lock In The 81.5% Run: Initiating Verve With A Sell (NASDAQ:VERV) - Seeking Alpha
Canaccord Genuity Downgrades Verve Therapeutics to Hold From Buy - marketscreener.com
HC Wainwright Downgrades Verve Therapeutics to Neutral From Buy, $25 Price Target - MarketScreener
Verve Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Hold Rating on Verve Therapeutics Acquisition by Eli Lilly: Fair Valuation with Low Competing Bid Potential - TipRanks
Verve Therapeutics (VERV) Downgraded After Acquisition Agreement | VERV Stock News - GuruFocus
Lilly Eyes Future of One-Time Cardiovascular Health with $1.3B Verve Therapeutics Acquisition - geneonline.com
Verve Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks
Jefferies cuts Verve Therapeutics stock rating on Lilly acquisition news - Investing.com
M&A News: Verve Therapeutics Stock (VERV) Rallies 75% on News of Potential Acquisition by Eli Lilly - The Globe and Mail
Eli Lilly to acquire for Verve Therapeutics for up to $1.3B - MSN
Verve Therapeutics (VERV) Downgraded Following Acquisition Annou - GuruFocus
Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High? - MSN
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover - MSN
Eli Lilly lands “bargain” deal to acquire Verve Therapeutics for $1.3bn - MSN
Why Verve Therapeutics Stock Is Skyrocketing Today - MSN
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say - The Mighty 790 KFGO
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say By Reuters - Investing.com
Lilly to acquire Verve Therapeutics for up to $1.3 billion By Investing.com - Investing.com South Africa
Verve Therapeutics (VERV) Downgraded by William Blair | VERV Sto - GuruFocus
Verve Therapeutics (VERV) Downgraded by Canaccord Genuity | VERV Stock News - GuruFocus
In a $1.3B deal, Lilly buys gene editor Verve - BioWorld MedTech
Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve - insights.citeline.com
Wilson Sonsini Advises Verve Therapeutics on IP Matters Related to Merger with Lilly - Wilson Sonsini
Stocks to Watch Recap: T-Mobile, Eli Lilly, Verve Therapeutics, First Solar - WSJ
These Stocks Moved the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More - Barron's
Verve Therapeutics downgraded to Market Perform from Outperform at LifeSci - TipRanks
Eli Lilly strikes $1.3 billion deal to buy gene-editing biotech Verve Therapeutics, companies say - MSN
Hold Rating on Verve Therapeutics Amid Acquisition and Development Milestones - TipRanks
Verve Therapeutics (VERV) Receives Downgrade Following Acquisiti - GuruFocus
Eli Lilly Gets Into The Gene-Editing Space With $1 Billion Takeout - Investor's Business Daily
Verve: Eli Lilly Acquisition Based On One-Time GalNAc PCSK9 Gene Editing Program - Seeking Alpha
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - MSN
William Blair Downgrades Verve Therapeutics (VERV) Amid Acquisit - GuruFocus
5 Analysts Assess Verve Therapeutics: What You Need To Know - Benzinga
Lilly to Acquire Verve Therapeutics in $1.3B Deal Targeting One-Time Gene-Editing Treatments for Cardiovascular Disease - BioPharm International
Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs - upi.com
Eli Lilly lands "bargain" deal to acquire Verve Therapeutics for $1.3bn - Pharmaceutical Technology
Verve Therapeutics (VERV) Stock Explodes Nearly 80% in a Single Day on Overwhelmingly Positive Momentum - Daily Chhattisgarh News
Eli Lilly Buys Verve Therapeutics: Aims To Permanently Lower Your Cholesterol (NYSE:LLY) - Seeking Alpha
Eli Lilly (NYSE:LLY) Eyes US$1.3 Billion Acquisition Of Verve Therapeutics - Yahoo Finance
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion - MSN
Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade) - Seeking Alpha
Stocks making the biggest moves midday: Jabil, JetBlue, Sunrun, Valero, Verve Therapeutics and more - CNBC
Eli Lilly Bets Big On Gene Editing With Verve Deal - Finimize
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
1.37%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):